ZOKINVY

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Israel, Italy, Lithuania.

Active ingredients

The drug ZOKINVY contains one active pharmaceutical ingredient (API):

1	Lonafarnib UNII IOW153004F - LONAFARNIB
	Lonafarnib is a disease modifying agent that prevents farnesylation, thereby reducing the accumulation of aberrant progerin and progerin-like proteins in the cell’s inner nuclear membrane. This results in maintaining cell integrity and normal function.
	Read more about Lonafarnib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZOKINVY Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AX20		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AX Various alimentary tract and metabolism products
Discover more medicines within A16AX20

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3046788, 3046799
FR	Base de données publique des médicaments	61837140, 66601425
IL	מִשְׂרַד הַבְּרִיאוּת	9043, 9044
IT	Agenzia del Farmaco	050224017, 050224029
LT	Valstybinė vaistų kontrolės tarnyba	1095122, 1095123
US	FDA, National Drug Code	73079-050, 73079-075